skip to main content

COPD ICS pneumonia risk — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardRespiratory TherapeuticsCOPD ICS pneumonia riskGPhC CRA

A COPD patient on high-dose inhaled corticosteroid has had two pneumonias in a year and asks if the inhaler matters. What would you advise the patient?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Arrange review of inhaled corticosteroid risk

High-dose inhaled corticosteroids in COPD can increase pneumonia risk and should be reviewed. In this scenario, the pharmacist should prioritise safe supply, appropriate counselling and timely referral or clarification where needed. This is the single best answer because the other options would either delay assessment, ignore a clinically significant risk, or create an unsafe legal or professional outcome.

Reference: https://www.pharmacyregulation.org/students-and-trainees/pharmacist-education-and-training/registration-assessment